Biomedical Dual-Action Imaging Probes for Cancer Therapy

用于癌症治疗的生物医学双作用成像探针

• 批准号: 2759586
• 金额: --
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2759586
• 关键词: Biomedical; Dual; Action; Imaging; Probes

This project aims to synthesize a series of dual-action therapeutic probes as novel anticancer agents. The compounds will incorporate an imidazole-based heme oxygenase-1 (HO-1) inhibitor along with an anti-cancer drug (e.g. PS, intercalating agent) to target tumors more susceptible to drug resistance. HO-1 regulates the concentration of cytotoxic free heme, but it is also known has a defensive role in cancers where it is overexpressed. Therefore, inhibiting HO-1 provides a possible alternative strategy in treating cancer. Examples in the literature have demonstrated the use of combinational therapy to overcome cancer resistance leading to an increased effectiveness in treatment. For example, Canti and co-workers discovered that the combinatorial administration of AlS2Pc, a photosensitizer (PS) used in photodynamic therapy, and chemotherapy drugs (i.e. Adriamycin and cisplatin) produced a synergistic therapeutic effect on murine tumors. In light of that, there is potential that a combinatorial probe that incorporates a PS for use in photodynamic therapy or an intercalating agent for use in chemotherapy while simultaneously inhibiting HO-1 activity can improve the success rate of the anticancer treatment.

本项目旨在合成一系列双作用治疗探针作为新型抗癌药物。这些化合物将结合咪唑基血红素加氧酶-1 （HO-1）抑制剂和抗癌药物（如PS，插层剂）来靶向更容易产生耐药性的肿瘤。HO-1调节细胞毒性游离血红素的浓度，但它也被认为在过度表达的癌症中具有防御作用。因此，抑制HO-1为治疗癌症提供了一种可能的替代策略。文献中的例子已经证明了使用联合疗法来克服癌症耐药性，从而提高了治疗的有效性。例如，Canti及其同事发现，光动力治疗中使用的光敏剂（PS） AlS2Pc与化疗药物（即阿霉素和顺铂）联合使用对小鼠肿瘤产生协同治疗作用。鉴于此，结合用于光动力治疗的PS或用于化疗的插入剂，同时抑制HO-1活性的组合探针有可能提高抗癌治疗的成功率。